Beijing Konruns Pharmaceutical Co., Ltd

Founded in   2003          Stock Code：  603590

Beijing Konruns Pharmaceutical Co., Ltd., founded in 2003, is dedicated to the core mission of "Protecting Human Health with life science." For the past twenty years, Konruns has emerged as a high-tech pharmaceutical enterprise that integrates research, manufacturing, and commercialization by aspiring to new drug R&D, especially groundbreaking product innovations. In August 2018, Konruns was successfully listed on the Shanghai Stock Exchange. 

Since its inception, the company has unwaveringly pursued new drug development and strived for excellence, emphasizing originality and innovation. Konruns currently possesses a class I new drug on the market, Suling®（Haemocoagulase Agkistrodon for Injection）. 

In 2020, the company expanded its product portfolio through the acquisition of Miacalcic Salmon Calcitonin Injection and Nasal Spray, bringing new sources of profit growth. 

At present, the company has a pipeline of several class I new drugs in development, including KC1036, ZY5301, and KC-B173. Konruns holds 65 national and international invention patents and has been awarded numerous top national honors, including National High-tech R&D Program (863 Program) Award, China Torch Program Award, and China Patent Excellence Award, etc.

Konruns possesses small molecular and biological drugs manufacturing sites located in Zhongguancun Miyun Park, Cangzhou Industrial Park, and Heze Industrial Park where there are production lines that conform to international standards with rigorous quality management and monitoring systems. By adhering to the maxim of "Quality Means Life”, the production team of Konruns pursues strict production and quality management. High-quality products have been launched onto the market and received high praise from doctors and patients.

⦿ Manufacturing sites- Miyun，Beijing

Manufacturing sites - Miyun was established in 2003 and is located in the Zhongguancun Miyun Economic Development Zone in Miyun District of Beijing, China. It covers an area of 117,500 square meters and includes production workshops that conform to international standards recognized by both NMPA and EMA for manufacturing oncology and common formulations of drugs, including injectables and oral solids.

⦿ Manufacturing sites-Cangzhou, Hebei

The Cangzhou site was established in 2013 and is located in the western zone of the Lingang Economic and Technological Development Zone in Cangzhou City, Hebei Province. It covers an area of 41,700 square meters and includes multiple workshops for the synthesis of active pharmaceutical ingredients (APIs), as well as supporting facilities such as a power plant, quality inspection center, raw material warehouse, finished goods warehouse, and a Class A warehouse. 

⦿ Breeding Site- Changde,Hunan

The Changde site was established in 2012 and is located in Taoyuan County, Changde City, Hunan Province, China. It is engaged in the breeding of Agkistrodon acutus, the extraction of venom, and related processing activities. The site covers an area of approximately 2,000 square meters and is equipped with state-of-the-art facilities, essential first-aid supplies, and a crew of knowledgeable and skilled specialists and caretakers.

⦿ Manufacturing sites-Germany

⦿ Manufacturing sites-France

Enterprise Honor

Konruns' exceptional achievements over the past two decades have earned the company numerous top national awards, including National High-tech R&D Program (863 Program) Award, China Torch Program Award, and China Patent Excellence Award, etc. These honors signify the government's endorsement, acknowledgment from scientific institutions, and recognition from social organizations, affirming Konruns' comprehensive strength, research achievements, and contributions to society.